The Business of Biofabrication

Japan is poised to reach a historic milestone in regenerative medicine. A panel of experts advising the country’s Ministry of Health, Labour and Welfare has conditionally endorsed two therapies derived from induced pluripotent stem (iPS) cells, potentially paving the way for the world’s first approved commercial products based on the technology.

The recommendation, issued in February 2026, allows the therapies to move forward toward manufacturing and commercialization, pending final approval by Japan’s health minister, expected within the next one to two months. If approved, the treatments would represent the first real-world clinical deployment of iPS cell-derived regenerative products, marking a major step for a technology first introduced less than two decades ago.

Two Pioneering Therapies

The panel reviewed two regenerative medicine products targeting serious and currently difficult-to-treat conditions.

The first therapy was developed by Cuorips, a startup originating from Osaka University. The company created sheets of cardiomyocytes, heart muscle cells derived from iPS cells. These patches are designed to treat ischemic cardiomyopathy, a severe form of heart disease caused by reduced blood supply to the heart muscle. By implanting functional heart cells, the therapy aims to restore damaged cardiac tissue and improve heart function.

The second product was developed by Sumitomo Pharma, which submitted a therapy consisting of dopaminergic neurons intended for transplantation into the brains of patients with Parkinson’s disease. Parkinson’s results from the degeneration of dopamine-producing neurons, leading to symptoms such as tremors, stiffness, and impaired movement. The therapy seeks to replace these lost neurons and restore neurological function.

Both companies applied for approval in 2025.

Conditional Approval Model

The therapies were evaluated under Japan’s conditional approval system for regenerative medicine, which allows promising treatments to reach patients earlier while additional clinical data continues to be gathered.

Under this framework, the companies must conduct follow-up studies involving all treated patients and collect additional data to confirm efficacy and long-term safety over a period of up to seven years.

While iPS cells offer major advantages, particularly the ability to generate many types of specialized cells from a patient’s own tissue, long-term safety remains a central question. Monitoring outcomes after commercialization will therefore be essential.

From Discovery to Clinical Reality

Induced pluripotent stem cells were first announced in 2006 by Kyoto University researcher Shinya Yamanaka, who later received the Nobel Prize for the discovery. The technology allows adult cells to be reprogrammed into a pluripotent state, enabling them to differentiate into nearly any cell type in the human body.

Since then, iPS cell research has expanded rapidly, with clinical trials conducted in Japan for approximately 20 different diseases. Applications range from cardiac repair and neurodegenerative disorders to retinal diseases and blood disorders.

The speed with which these two therapies have progressed, from discovery to near-commercial use in less than two decades, has been notable. Experts attribute this progress partly to strong national support for regenerative medicine, including targeted funding programs and regulatory frameworks designed to accelerate clinical translation.

The Next Phase: Proving Real-World Impact

Despite the milestone, experts emphasize that true success will depend on long-term outcomes and real-world adoption.

Ryo Hanamura, a business consultant who previously served on Japan’s national committee on regenerative medicine, noted that the technology’s promise will only be fulfilled if it ultimately improves the lives of large numbers of patients and attracts sustained investment into the field.

That investment cycle linking scientific breakthroughs, clinical success, and commercial viability will be critical for maintaining Japan’s leadership in regenerative medicine as global competition intensifies.

With final approval expected soon, the therapies developed by Cuorips and Sumitomo Pharma may soon become the first tangible demonstration that iPS cell science can move from the laboratory into everyday clinical medicine, a milestone many in the regenerative medicine community have been anticipating for nearly twenty years.